Short-term Safety and Efficacy of Intravitreal Bavacizumab Injection. |
Su Jin Kim, Young Min Park, Seung Uk Lee, Ji Eun Lee, Boo Sup Oum |
Department of Ophthalmology, College of Medicine, Pusan National University, Pusan, Korea. jlee@pusan.ac.kr |
유리체강속 베바시주맙 주사의 단기간 안전성 및 효용성 |
김수진ㆍ박영민ㆍ이승욱ㆍ이지은ㆍ엄부섭 |
Department of Ophthalmology, College of Medicine, Pusan National University, Pusan, korea |
|
Abstract |
PURPOSE To evaluate the short-term safety and efficacy of intravitreal bevacizumab (Avastin(R)) injection for various conditions. METHODS: The medical records of 257 eyes of 251 patients who underwent intravitreal bevacizumab injections were reviewed. Central retinal thickness on optical coherence tomography and visual acuity before injections, at 1 week, 1 month, 2 months and 3 months after injections were analyzed. RESULTS: The patients included age-related macular degeneration (89 eyes), diabetic macular edema (67 eyes) and retinal vascular occlusion (57 eyes). The number of injections was twice in 82 eyes, 3 times in 23 eyes and 4 times in 2 eyes. In total, 391 injections were performed. Best corrected visual acuity increased significantly at 3 months (p=0.033) and central retinal thickness decreased by 1 month and was maintained until 3 months after the first injection (p<0.001). No serious drug-related ocular or systemic adverse incidents including endophthalmitis, glaucoma, retinal detachment, hypertension or myocardial infarction were identified. CONCLUSIONS: The intravitreal bevacizumab injection was safe and efficient for macular edema in this short-term study. |
Key Words:
Bevacizumab;Efficacy;Safety |
|